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Background: Patients at high risk for a major cardiovascular event (MCVE) are treated with effective drugs that significantly reduce the risk of a 
future event. It is currently uncertain how much additional lowering of atherogenic lipoproteins (beyond that achieved with high-dose statins) would 
contribute to a further reduction in the risk of a future MCVE. Nor is it known whether measurements of atherogenic lipoprotein levels in statin-
treated patients adds significantly to risk prediction beyond the risk predicted by traditional non-lipid risk factors.
Methods: We addressed this issue using a prognostic (distinct from an etiological) analysis approach in high-risk stable coronary heart disease 
(CHD) patients from the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) and Treating to New Targets (TNT) trials.
Results: In a two-thirds training sample of the IDEAL trial, eleven baseline factors were significantly associated with subsequent MCVEs. When these 
factors were fitted to the remaining one-third test sample, only age, smoking, diabetes, history of cerebrovascular disease and uric acid remained as 
clearly significant. External calibration versus TNT data was generally good. On-treatment lipoprotein levels increased discrimination ability only to a 
minor degree.
Conclusions: This analysis suggests that among high-risk CHD patients on statin therapy, strategies for further risk reduction should include 
targeting other modifiable factors such as smoking, diabetes and blood pressure control. Formulas for calculation of individual 5-year probabilities 
of residual MCVEs for simvastatin- or atorvastatin-treated patients with CHD are now provided and can easily be used for individual risk calculations 
or risk stratification in planning future trials. 
